HEADER TRANSFERASE/CELL CYCLE 02-OCT-12 4BCQ TITLE STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- TITLE 2 HETEROARYL-PYRIMIDINE INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: CYCLIN-DEPENDENT KINASE 2; COMPND 3 CHAIN: A, C; COMPND 4 SYNONYM: 2.7.11.22, CELL DIVISION PROTEIN KINASE 2, P33 PROTEIN COMPND 5 KINASE; COMPND 6 EC: 2.7.11.22; COMPND 7 ENGINEERED: YES; COMPND 8 MOL_ID: 2; COMPND 9 MOLECULE: CYCLIN-A2; COMPND 10 CHAIN: B; COMPND 11 FRAGMENT: RESIDUES 169-429; COMPND 12 SYNONYM: CYCLIN-A; COMPND 13 ENGINEERED: YES; COMPND 14 MOL_ID: 3; COMPND 15 MOLECULE: CYCLIN-A2; COMPND 16 CHAIN: D; COMPND 17 FRAGMENT: RESIDUES 169-429; COMPND 18 SYNONYM: CYCLIN-A; COMPND 19 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 7 MOL_ID: 2; SOURCE 8 ORGANISM_SCIENTIFIC: BOS TAURUS; SOURCE 9 ORGANISM_COMMON: CATTLE; SOURCE 10 ORGANISM_TAXID: 9913; SOURCE 11 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 12 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 13 MOL_ID: 3; SOURCE 14 ORGANISM_SCIENTIFIC: BOS TAURUS; SOURCE 15 ORGANISM_COMMON: CATTLE; SOURCE 16 ORGANISM_TAXID: 9913; SOURCE 17 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 18 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS TRANSFERASE-CELL CYCLE COMPLEX, CDK-CYCLIN COMPLEX, CYCLIN A, KEYWDS 2 CYCLIN- DEPENDENT KINASE 2, STRUCTURE-BASED DRUG DESIGN EXPDTA X-RAY DIFFRACTION AUTHOR A.J.HOLE,S.BAUMLI,S.WANG,J.A.ENDICOTT,M.E.M.NOBLE REVDAT 2 27-FEB-13 4BCQ 1 JRNL REVDAT 1 09-JAN-13 4BCQ 0 JRNL AUTH A.J.HOLE,S.BAUMLI,H.SHAO,S.SHI,C.PEPPER,P.M.FISCHER,S.WANG, JRNL AUTH 2 J.A.ENDICOTT,M.E.M.NOBLE JRNL TITL COMPARATIVE STRUCTURAL AND FUNCTIONAL STUDIES OF JRNL TITL 2 4-(THIAZOL- 5-YL)-2-(PHENYLAMINO)PYRIMIDINE-5-CARBONITRILE JRNL TITL 3 CDK9 INHIBITORS SUGGEST THE BASIS FOR ISOTYPE SELECTIVITY. JRNL REF J.MED.CHEM. V. 56 660 2013 JRNL REFN ISSN 0022-2623 JRNL PMID 23252711 JRNL DOI 10.1021/JM301495V REMARK 2 REMARK 2 RESOLUTION. 2.40 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX (PHENIX.REFINE) REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VICENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : ML REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.400 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 48.662 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.34 REMARK 3 COMPLETENESS FOR RANGE (%) : 97.45 REMARK 3 NUMBER OF REFLECTIONS : 65380 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.2171 REMARK 3 R VALUE (WORKING SET) : 0.2152 REMARK 3 FREE R VALUE : 0.2518 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.1 REMARK 3 FREE R VALUE TEST SET COUNT : 3315 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 48.6723 - 6.9164 0.99 2852 143 0.1849 0.1685 REMARK 3 2 6.9164 - 5.4922 0.95 2618 127 0.2106 0.2324 REMARK 3 3 5.4922 - 4.7987 0.98 2636 153 0.1578 0.1927 REMARK 3 4 4.7987 - 4.3602 0.99 2651 145 0.1504 0.2106 REMARK 3 5 4.3602 - 4.0479 0.99 2649 138 0.1722 0.2092 REMARK 3 6 4.0479 - 3.8093 0.99 2647 148 0.1844 0.2295 REMARK 3 7 3.8093 - 3.6186 1.00 2604 182 0.2006 0.2434 REMARK 3 8 3.6186 - 3.4611 0.99 2622 163 0.2144 0.2518 REMARK 3 9 3.4611 - 3.3279 1.00 2638 132 0.2294 0.2617 REMARK 3 10 3.3279 - 3.2131 0.99 2611 129 0.2513 0.2966 REMARK 3 11 3.2131 - 3.1127 1.00 2658 144 0.2539 0.3312 REMARK 3 12 3.1127 - 3.0237 1.00 2660 125 0.2670 0.2936 REMARK 3 13 3.0237 - 2.9441 1.00 2600 142 0.2629 0.3058 REMARK 3 14 2.9441 - 2.8723 0.99 2623 128 0.2594 0.3246 REMARK 3 15 2.8723 - 2.8070 0.99 2612 144 0.2620 0.2857 REMARK 3 16 2.8070 - 2.7473 0.99 2618 130 0.2594 0.2700 REMARK 3 17 2.7473 - 2.6923 0.98 2548 142 0.2551 0.3338 REMARK 3 18 2.6923 - 2.6415 0.98 2593 127 0.2698 0.3131 REMARK 3 19 2.6415 - 2.5943 0.96 2502 138 0.2664 0.3016 REMARK 3 20 2.5943 - 2.5504 0.95 2476 133 0.2781 0.3463 REMARK 3 21 2.5504 - 2.5092 0.94 2465 141 0.3027 0.3502 REMARK 3 22 2.5092 - 2.4706 0.93 2443 130 0.2972 0.3648 REMARK 3 23 2.4706 - 2.4343 0.91 2363 117 0.3264 0.4227 REMARK 3 24 2.4343 - 2.4000 0.90 2376 114 0.3205 0.3748 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.30 REMARK 3 SHRINKAGE RADIUS : 1.11 REMARK 3 K_SOL : 0.343 REMARK 3 B_SOL : 71.996 REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.42 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 24.51 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 43.82 REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 3.3092 REMARK 3 B22 (A**2) : -0.4663 REMARK 3 B33 (A**2) : -2.8428 REMARK 3 B12 (A**2) : 0.0000 REMARK 3 B13 (A**2) : 0.0000 REMARK 3 B23 (A**2) : 0.0000 REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.004 9173 REMARK 3 ANGLE : 0.800 12461 REMARK 3 CHIRALITY : 0.056 1400 REMARK 3 PLANARITY : 0.004 1562 REMARK 3 DIHEDRAL : 14.024 3432 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 8 REMARK 3 TLS GROUP : 1 REMARK 3 SELECTION: CHAIN A AND (RESSEQ -1:85) REMARK 3 ORIGIN FOR THE GROUP (A): 11.1792 14.4087 25.8682 REMARK 3 T TENSOR REMARK 3 T11: 0.2239 T22: 0.2994 REMARK 3 T33: 0.2334 T12: -0.0286 REMARK 3 T13: 0.0352 T23: -0.0071 REMARK 3 L TENSOR REMARK 3 L11: 0.7498 L22: 1.4246 REMARK 3 L33: 2.4454 L12: -0.1182 REMARK 3 L13: 0.2174 L23: 0.7039 REMARK 3 S TENSOR REMARK 3 S11: 0.0201 S12: -0.1520 S13: -0.1372 REMARK 3 S21: 0.2782 S22: -0.2764 S23: 0.1107 REMARK 3 S31: 0.1612 S32: -0.4603 S33: 0.1953 REMARK 3 TLS GROUP : 2 REMARK 3 SELECTION: CHAIN A AND (RESSEQ 86:298) REMARK 3 ORIGIN FOR THE GROUP (A): 4.5688 32.6173 4.0362 REMARK 3 T TENSOR REMARK 3 T11: 0.0725 T22: 0.1865 REMARK 3 T33: 0.1654 T12: 0.0023 REMARK 3 T13: 0.0150 T23: -0.0040 REMARK 3 L TENSOR REMARK 3 L11: 1.1681 L22: 0.2998 REMARK 3 L33: 0.5832 L12: -0.2567 REMARK 3 L13: 0.5174 L23: -0.2246 REMARK 3 S TENSOR REMARK 3 S11: 0.0296 S12: 0.0750 S13: 0.1202 REMARK 3 S21: 0.0474 S22: -0.0336 S23: -0.0796 REMARK 3 S31: -0.0310 S32: -0.0359 S33: -0.0024 REMARK 3 TLS GROUP : 3 REMARK 3 SELECTION: CHAIN B REMARK 3 ORIGIN FOR THE GROUP (A): 22.1896 -0.2730 -2.8565 REMARK 3 T TENSOR REMARK 3 T11: 0.1692 T22: 0.1642 REMARK 3 T33: 0.1541 T12: 0.0064 REMARK 3 T13: -0.0021 T23: -0.0299 REMARK 3 L TENSOR REMARK 3 L11: 0.7411 L22: 1.3787 REMARK 3 L33: 1.2259 L12: 0.4748 REMARK 3 L13: -0.2809 L23: -0.1437 REMARK 3 S TENSOR REMARK 3 S11: -0.0475 S12: 0.0878 S13: -0.0203 REMARK 3 S21: -0.0823 S22: 0.0175 S23: -0.0675 REMARK 3 S31: 0.2504 S32: -0.0616 S33: 0.0203 REMARK 3 TLS GROUP : 4 REMARK 3 SELECTION: CHAIN C AND (RESSEQ -1:85) REMARK 3 ORIGIN FOR THE GROUP (A): 29.7982 -8.1587 32.9706 REMARK 3 T TENSOR REMARK 3 T11: 0.3785 T22: 0.3232 REMARK 3 T33: 0.1792 T12: 0.0343 REMARK 3 T13: -0.0456 T23: 0.0811 REMARK 3 L TENSOR REMARK 3 L11: 0.3046 L22: 0.9903 REMARK 3 L33: 0.6995 L12: 0.0724 REMARK 3 L13: 0.2258 L23: 0.7227 REMARK 3 S TENSOR REMARK 3 S11: 0.1251 S12: -0.1441 S13: -0.0173 REMARK 3 S21: 0.2521 S22: -0.1019 S23: -0.0017 REMARK 3 S31: 0.2513 S32: -0.1447 S33: -0.0076 REMARK 3 TLS GROUP : 5 REMARK 3 SELECTION: CHAIN C AND (RESSEQ 86:298) REMARK 3 ORIGIN FOR THE GROUP (A): 57.6830 -14.4279 36.0092 REMARK 3 T TENSOR REMARK 3 T11: 0.3193 T22: 0.4443 REMARK 3 T33: 0.4072 T12: 0.0814 REMARK 3 T13: -0.0208 T23: 0.1938 REMARK 3 L TENSOR REMARK 3 L11: 0.8442 L22: 1.6680 REMARK 3 L33: 0.7944 L12: -0.0571 REMARK 3 L13: 0.7046 L23: -0.7743 REMARK 3 S TENSOR REMARK 3 S11: 0.1656 S12: 0.0402 S13: -0.0060 REMARK 3 S21: -0.1758 S22: -0.3547 S23: -0.8116 REMARK 3 S31: 0.0854 S32: 0.3419 S33: 0.1068 REMARK 3 TLS GROUP : 6 REMARK 3 SELECTION: CHAIN D REMARK 3 ORIGIN FOR THE GROUP (A): 46.0434 21.8289 36.0408 REMARK 3 T TENSOR REMARK 3 T11: 0.3439 T22: 0.3210 REMARK 3 T33: 0.2488 T12: -0.1707 REMARK 3 T13: -0.0820 T23: 0.0941 REMARK 3 L TENSOR REMARK 3 L11: 1.3383 L22: 1.7892 REMARK 3 L33: 1.1323 L12: -0.3883 REMARK 3 L13: -0.1339 L23: -0.2424 REMARK 3 S TENSOR REMARK 3 S11: 0.0081 S12: -0.1692 S13: 0.3264 REMARK 3 S21: 0.0450 S22: -0.2217 S23: -0.4348 REMARK 3 S31: -0.1693 S32: 0.3691 S33: 0.0525 REMARK 3 TLS GROUP : 7 REMARK 3 SELECTION: CHAIN A AND (RESSEQ 1296) REMARK 3 ORIGIN FOR THE GROUP (A): 5.0449 23.7700 24.1580 REMARK 3 T TENSOR REMARK 3 T11: 0.6527 T22: 0.8498 REMARK 3 T33: 0.6654 T12: -0.1720 REMARK 3 T13: -0.1761 T23: 0.1373 REMARK 3 L TENSOR REMARK 3 L11: 0.0053 L22: 0.0244 REMARK 3 L33: 0.0025 L12: -0.0111 REMARK 3 L13: 0.0035 L23: -0.0075 REMARK 3 S TENSOR REMARK 3 S11: -0.0941 S12: 0.1769 S13: -0.0146 REMARK 3 S21: -0.0619 S22: -0.2007 S23: 0.2351 REMARK 3 S31: -0.0645 S32: -0.1703 S33: -0.0031 REMARK 3 TLS GROUP : 8 REMARK 3 SELECTION: CHAIN C AND (RESSEQ 1295) REMARK 3 ORIGIN FOR THE GROUP (A): 35.0428 -18.5757 32.6644 REMARK 3 T TENSOR REMARK 3 T11: 0.8739 T22: 0.9637 REMARK 3 T33: 0.7815 T12: 0.4487 REMARK 3 T13: -0.1997 T23: 0.0396 REMARK 3 L TENSOR REMARK 3 L11: 0.1351 L22: 1.1535 REMARK 3 L33: 0.4403 L12: -0.1497 REMARK 3 L13: -0.0417 L23: -0.3634 REMARK 3 S TENSOR REMARK 3 S11: -0.1911 S12: -0.1403 S13: -0.1976 REMARK 3 S21: 0.2500 S22: -0.0458 S23: 0.0000 REMARK 3 S31: 0.0698 S32: 0.1137 S33: -0.0565 REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4BCQ COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 30-SEP-12. REMARK 100 THE PDBE ID CODE IS EBI-54257. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : NULL REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : DIAMOND REMARK 200 BEAMLINE : I04 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.98 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC REMARK 200 INTENSITY-INTEGRATION SOFTWARE : NULL REMARK 200 DATA SCALING SOFTWARE : NULL REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 65528 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.19 REMARK 200 RESOLUTION RANGE LOW (A) : 52.26 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NAN REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 97.9 REMARK 200 DATA REDUNDANCY : 3.20 REMARK 200 R MERGE (I) : 0.13 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 4.27 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.40 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.53 REMARK 200 COMPLETENESS FOR SHELL (%) : 93.0 REMARK 200 DATA REDUNDANCY IN SHELL : 2.91 REMARK 200 R MERGE FOR SHELL (I) : 0.46 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 1.65 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 63 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.4 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: COCRYSTALS WERE GROWN IN REMARK 280 1-1.25M AMMONIUM SULFATE, 0.5-0.9M KCL, 100MM HEPES, PH REMARK 280 7.0, 5MM DTT AND IN THE PRESENCE OF COMPOUND. REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 38.54000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 77.76000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 70.58000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 77.76000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 38.54000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 70.58000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 3060 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 25590 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -12.4 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 3050 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 25830 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -10.3 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLU A 12 REMARK 465 GLY A 13 REMARK 465 THR A 14 REMARK 465 TYR A 15 REMARK 465 GLY A 16 REMARK 465 LEU A 296 REMARK 465 ARG A 297 REMARK 465 LEU A 298 REMARK 465 SER B 171 REMARK 465 VAL B 172 REMARK 465 ASN B 173 REMARK 465 GLU B 174 REMARK 465 VAL B 175 REMARK 465 PRO C -2 REMARK 465 GLY C -1 REMARK 465 GLY C 13 REMARK 465 THR C 14 REMARK 465 HIS C 295 REMARK 465 LEU C 296 REMARK 465 ARG C 297 REMARK 465 LEU C 298 REMARK 465 SER D 171 REMARK 465 VAL D 172 REMARK 465 ASN D 173 REMARK 465 GLU D 174 REMARK 465 VAL D 175 REMARK 465 GLN D 323 REMARK 465 PRO D 324 REMARK 465 VAL D 432 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ALA B 357 CB REMARK 470 ALA D 357 CB REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HOH A 2116 O HOH A 2117 2.04 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR A 72 -146.02 -127.22 REMARK 500 SER A 94 51.85 -92.72 REMARK 500 ASP A 127 44.65 -153.09 REMARK 500 ASN A 136 -168.37 -115.64 REMARK 500 ASP A 145 84.99 62.82 REMARK 500 TYR A 159 -169.26 -112.44 REMARK 500 GLU A 162 72.71 55.62 REMARK 500 VAL A 164 133.29 69.33 REMARK 500 SER A 181 -146.62 -143.04 REMARK 500 THR A 290 -155.21 -128.90 REMARK 500 TRP B 372 107.65 -42.54 REMARK 500 THR C 41 -82.15 -130.82 REMARK 500 ASP C 127 43.66 -158.28 REMARK 500 ASN C 136 -169.22 -117.17 REMARK 500 ASP C 145 86.27 59.21 REMARK 500 ARG C 157 -167.96 -116.40 REMARK 500 TYR C 159 -163.58 -108.98 REMARK 500 VAL C 164 129.95 69.58 REMARK 500 SER C 181 -143.32 -152.70 REMARK 500 ASP C 223 -169.77 -127.49 REMARK 500 ASP C 256 -151.04 -93.59 REMARK 500 THR C 290 -167.16 -128.08 REMARK 500 HIS D 321 39.19 -96.46 REMARK 500 TRP D 372 106.03 -47.57 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE TJF A1296 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE TJF C1295 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1AQ1 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE REMARK 900 INHIBITOR STAUROSPORINE REMARK 900 RELATED ID: 1B38 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1B39 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR REMARK 900 160 REMARK 900 RELATED ID: 1BUH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX REMARK 900 WITHCELL CYCLE-REGULATORY PROTEIN CKSHS1 REMARK 900 RELATED ID: 1CKP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE REMARK 900 INHIBITOR PURVALANOL B REMARK 900 RELATED ID: 1DI8 RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN REMARK 900 COMPLEX WITH 4-[3- HYDROXYANILINO]-6,7- REMARK 900 DIMETHOXYQUINAZOLINE REMARK 900 RELATED ID: 1DM2 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE REMARK 900 INHIBITOR HYMENIALDISINE REMARK 900 RELATED ID: 1E1V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE REMARK 900 INHIBITOR NU2058 REMARK 900 RELATED ID: 1E1X RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE REMARK 900 INHIBITOR NU6027 REMARK 900 RELATED ID: 1E9H RELATED DB: PDB REMARK 900 THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX REMARK 900 WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND REMARK 900 RELATED ID: 1F5Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN REMARK 900 COMPLEXED TO HUMAN CYCLIN DEPENDANT KINASE 2 REMARK 900 RELATED ID: 1FIN RELATED DB: PDB REMARK 900 CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX REMARK 900 RELATED ID: 1FQ1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) REMARK 900 INCOMPLEX WITH PHOSPHO-CDK2 REMARK 900 RELATED ID: 1FVT RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) REMARK 900 INCOMPLEX WITH AN OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1FVV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN REMARK 900 OXINDOLEINHIBITOR REMARK 900 RELATED ID: 1G5S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 ( REMARK 900 CDK2)IN COMPLEX WITH THE INHIBITOR H717 REMARK 900 RELATED ID: 1GIH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE REMARK 900 CDK4INHIBITOR REMARK 900 RELATED ID: 1GII RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE REMARK 900 CDK4INHIBITOR REMARK 900 RELATED ID: 1GIJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE REMARK 900 CDK4INHIBITOR REMARK 900 RELATED ID: 1GY3 RELATED DB: PDB REMARK 900 PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND REMARK 900 PEPTIDE SUBSTRATE REMARK 900 RELATED ID: 1GZ8 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE REMARK 900 INHIBITOR 2-AMINO-6-(3'-METHYL-2'-OXO)BUTOXYPURINE REMARK 900 RELATED ID: 1H00 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6-BIS REMARK 900 ANILINO PYRIMIDINE CDK4 INHIBITOR REMARK 900 RELATED ID: 1H01 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4-BIS REMARK 900 ANILINO PYRIMIDINE CDK4 INHIBITOR REMARK 900 RELATED ID: 1H07 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6-BIS REMARK 900 ANILINO PYRIMIDINE CDK4 INHIBITOR REMARK 900 RELATED ID: 1H08 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4-BIS REMARK 900 ANILINO PYRIMIDINE CDK4 INHIBITOR REMARK 900 RELATED ID: 1H0V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX REMARK 900 WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5'-YL REMARK 900 ]METHOXYPURINE REMARK 900 RELATED ID: 1H0W RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX REMARK 900 WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL] REMARK 900 METHOXYPURINE REMARK 900 RELATED ID: 1H1P RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A REMARK 900 COMPLEXED WITH THE INHIBITOR NU2058 REMARK 900 RELATED ID: 1H1Q RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A REMARK 900 COMPLEXED WITH THE INHIBITOR NU6094 REMARK 900 RELATED ID: 1H1R RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A REMARK 900 COMPLEXED WITH THE INHIBITOR NU6086 REMARK 900 RELATED ID: 1H1S RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A REMARK 900 COMPLEXED WITH THE INHIBITOR NU6102 REMARK 900 RELATED ID: 1H24 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT REMARK 900 PEPTIDE FROM E2F REMARK 900 RELATED ID: 1H25 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT REMARK 900 PEPTIDE FROM E2F REMARK 900 RELATED ID: 1H26 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT REMARK 900 PEPTIDE FROM P53 REMARK 900 RELATED ID: 1H27 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT REMARK 900 PEPTIDE FROM P27 REMARK 900 RELATED ID: 1H28 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT REMARK 900 PEPTIDE FROM P107 REMARK 900 RELATED ID: 1HCK RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1HCL RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1JST RELATED DB: PDB REMARK 900 PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN REMARK 900 A REMARK 900 RELATED ID: 1JSU RELATED DB: PDB REMARK 900 P27(KIP1)/CYCLIN A/CDK2 COMPLEX REMARK 900 RELATED ID: 1JSV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) REMARK 900 INCOMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL)AMINO] REMARK 900 BENZENESULFONAMIDE REMARK 900 RELATED ID: 1JVP RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) REMARK 900 INCOMPLEX WITH PKF049-365 REMARK 900 RELATED ID: 1KE5 RELATED DB: PDB REMARK 900 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-1,2- REMARK 900 DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO} REMARK 900 BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE6 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N- REMARK 900 METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO REMARK 900 [5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL} REMARK 900 METHANESULFONAMIDE REMARK 900 RELATED ID: 1KE7 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2 REMARK 900 ,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO] REMARK 900 METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H- REMARK 900 INDOL-2-ONE REMARK 900 RELATED ID: 1KE8 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2 REMARK 900 -OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}- REMARK 900 N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE9 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4 REMARK 900 -({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2 REMARK 900 -OXO-2,3-DIHYDRO-1H-INDOLE REMARK 900 RELATED ID: 1OGU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A REMARK 900 COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5- REMARK 900 NITROSO-6-AMINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1OI9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A REMARK 900 COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1OIQ RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN REMARK 900 -DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE- REMARK 900 BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIR RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN REMARK 900 -DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE- REMARK 900 BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIT RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN REMARK 900 -DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE- REMARK 900 BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A REMARK 900 COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1OIY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A REMARK 900 COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1OKV RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE REMARK 900 -PHE-NH2 REMARK 900 RELATED ID: 1OKW RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN REMARK 900 -(M-CL-PHE)-NH2 REMARK 900 RELATED ID: 1OL1 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE REMARK 900 -(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1OL2 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN REMARK 900 -(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1P2A RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH REMARK 900 ATRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR REMARK 900 RELATED ID: 1P5E RELATED DB: PDB REMARK 900 THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX REMARK 900 WITH THEINHIBITOR 4,5,6,7-TETRABROMOBENZOTRIAZOLE (TBS) REMARK 900 RELATED ID: 1PF8 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE REMARK 900 2COMPLEXED WITH A NUCLEOSIDE INHIBITOR REMARK 900 RELATED ID: 1PKD RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH REMARK 900 PHOSPHO-CDK2/CYCLIN A REMARK 900 RELATED ID: 1PW2 RELATED DB: PDB REMARK 900 APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1PXI RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH REMARK 900 THEINHIBITOR 4-(2,5-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN REMARK 900 -2-YLAMINE REMARK 900 RELATED ID: 1PXJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH REMARK 900 THEINHIBITOR 4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN- REMARK 900 2-YLAMINE REMARK 900 RELATED ID: 1PXK RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH REMARK 900 THEINHIBITOR N-[4-(2,4-DIMETHYL-THIAZOL-5-YL) REMARK 900 PYRIMIDIN-2-YL]-N'-HYDROXYIMINOFORMAMIDE REMARK 900 RELATED ID: 1PXL RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH REMARK 900 THEINHIBITOR [4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN REMARK 900 -2-YL]-(4-TRIFLUOROMETHYL-PHENYL)-AMINE REMARK 900 RELATED ID: 1PXM RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH REMARK 900 THEINHIBITOR 3-[4-(2,4-DIMETHYL-THIAZOL-5-YL)- REMARK 900 PYRIMIDIN-2-YLAMINO]-PHENOL REMARK 900 RELATED ID: 1PXN RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH REMARK 900 THEINHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5- REMARK 900 YL)-PYRIMIDIN-2-YLAMINO]-PHENOL REMARK 900 RELATED ID: 1PXO RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH REMARK 900 THEINHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)- REMARK 900 PYRIMIDIN-2-YL]-(3-NITRO-PHENYL)-AMINE REMARK 900 RELATED ID: 1PXP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH REMARK 900 THEINHIBITOR N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)- REMARK 900 PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE REMARK 900 RELATED ID: 1PYE RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR REMARK 900 RELATED ID: 1QMZ RELATED DB: PDB REMARK 900 PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX REMARK 900 RELATED ID: 1R78 RELATED DB: PDB REMARK 900 CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1URC RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN REMARK 900 -(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1URW RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B]PYRIDAZINE REMARK 900 RELATED ID: 1V1K RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6-BIS REMARK 900 ANILINO PYRIMIDINE CDK4 INHIBITOR REMARK 900 RELATED ID: 1VIN RELATED DB: PDB REMARK 900 BOVINE CYCLIN A3 REMARK 900 RELATED ID: 1VYW RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137 REMARK 900 RELATED ID: 1VYZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227 REMARK 900 RELATED ID: 1W0X RELATED DB: PDB REMARK 900 CRYSTALS STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE REMARK 900 INHIBITOR OLOMOUCINE. REMARK 900 RELATED ID: 1W8C RELATED DB: PDB REMARK 900 CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL REMARK 900 -9H-PURIN-2-YLAMINE AND MONOMERIC CDK2 REMARK 900 RELATED ID: 1W98 RELATED DB: PDB REMARK 900 THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E REMARK 900 RELATED ID: 1WCC RELATED DB: PDB REMARK 900 SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY REMARK 900 RELATED ID: 1Y8Y RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A REMARK 900 PYRAZOLO[1,5-A]PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1Y91 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A REMARK 900 PYRAZOLO[1,5-A]PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1YKR RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO REMARK 900 PYRIDINEINHIBITOR REMARK 900 RELATED ID: 2A0C RELATED DB: PDB REMARK 900 HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II, A NOVEL 2 REMARK 900 ,6,9-TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2A4L RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH REMARK 900 ROSCOVITINE REMARK 900 RELATED ID: 2B52 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH REMARK 900 DPH-042562 REMARK 900 RELATED ID: 2B53 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH REMARK 900 DIN-234325 REMARK 900 RELATED ID: 2B54 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH REMARK 900 DIN-232305 REMARK 900 RELATED ID: 2B55 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED REMARK 900 WITHINDENOPYRAXOLE DIN-101312 REMARK 900 RELATED ID: 2BHE RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX REMARK 900 WITH THE INHIBITOR 5-BROMO-INDIRUBINE REMARK 900 RELATED ID: 2BHH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX REMARK 900 WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE REMARK 900 RELATED ID: 2BKZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611 REMARK 900 RELATED ID: 2BPM RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529 REMARK 900 RELATED ID: 2BTR RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873 REMARK 900 RELATED ID: 2BTS RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032 REMARK 900 RELATED ID: 2C4G RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514 REMARK 900 RELATED ID: 2C5N RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND REMARK 900 INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5O RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND REMARK 900 INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5V RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND REMARK 900 INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5X RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND REMARK 900 INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5Y RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND REMARK 900 INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C68 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C69 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6K RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6L RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6M RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6O RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6T RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2CCH RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX REMARK 900 WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED REMARK 900 WITH A GAMMA-LINKED ATP ANALOGUE REMARK 900 RELATED ID: 2CCI RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX REMARK 900 WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND REMARK 900 RECRUITMENT SITES OF CDC6 REMARK 900 RELATED ID: 2CJM RELATED DB: PDB REMARK 900 MECHANISM OF CDK INHIBITION BY ACTIVE SITE REMARK 900 PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN REMARK 900 A STRUCTURE REMARK 900 RELATED ID: 2CLX RELATED DB: PDB REMARK 900 4-ARYLAZO-3,5-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: REMARK 900 SAR STUDY, CRYSTAL STRUCTURE IN COMPLEX WITH CDK2, REMARK 900 SELECTIVITY, AND CELLULAR EFFECTS REMARK 900 RELATED ID: 2EXM RELATED DB: PDB REMARK 900 HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE REMARK 900 RELATED ID: 2G9X RELATED DB: PDB REMARK 900 STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A REMARK 900 INCOMPLEX WITH THE INHIBITOR NU6271 REMARK 900 RELATED ID: 2IW6 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A REMARK 900 COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2IW8 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H- REMARK 900 L83V-H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2IW9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A REMARK 900 COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2J9M RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC REMARK 900 AMINOPYRIMIDINE REMARK 900 RELATED ID: 2JGZ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH REMARK 900 CYCLIN B REMARK 900 RELATED ID: 2UUE RELATED DB: PDB REMARK 900 REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN REMARK 900 BINDING GROOVE INHIBITORS REMARK 900 RELATED ID: 2UZB RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A REMARK 900 THIAZOLIDINONE INHIBITOR REMARK 900 RELATED ID: 2UZD RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A REMARK 900 THIAZOLIDINONE INHIBITOR REMARK 900 RELATED ID: 2UZE RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A REMARK 900 THIAZOLIDINONE INHIBITOR REMARK 900 RELATED ID: 2UZL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A REMARK 900 THIAZOLIDINONE INHIBITOR REMARK 900 RELATED ID: 2UZN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A REMARK 900 THIAZOLIDINONE INHIBITOR REMARK 900 RELATED ID: 2UZO RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A REMARK 900 THIAZOLIDINONE INHIBITOR REMARK 900 RELATED ID: 2V0D RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A REMARK 900 THIAZOLIDINONE INHIBITOR REMARK 900 RELATED ID: 2V22 RELATED DB: PDB REMARK 900 REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN REMARK 900 BINDING GROOVE INHIBITORS REMARK 900 RELATED ID: 2VTA RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- REMARK 900 DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), REMARK 900 A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT REMARK 900 -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 2VTH RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- REMARK 900 DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), REMARK 900 A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT REMARK 900 -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 2VTI RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- REMARK 900 DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), REMARK 900 A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT REMARK 900 -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 2VTJ RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- REMARK 900 DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), REMARK 900 A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT REMARK 900 -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 2VTL RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- REMARK 900 DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), REMARK 900 A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT REMARK 900 -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 2VTM RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- REMARK 900 DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), REMARK 900 A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT REMARK 900 -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 2VTN RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- REMARK 900 DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), REMARK 900 A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT REMARK 900 -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 2VTO RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- REMARK 900 DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), REMARK 900 A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT REMARK 900 -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 2VTP RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- REMARK 900 DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), REMARK 900 A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT REMARK 900 -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 2VTQ RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- REMARK 900 DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), REMARK 900 A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT REMARK 900 -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 2VTR RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- REMARK 900 DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), REMARK 900 A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT REMARK 900 -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 2VTS RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- REMARK 900 DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), REMARK 900 A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT REMARK 900 -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 2VTT RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- REMARK 900 DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), REMARK 900 A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT REMARK 900 -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 2VU3 RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- REMARK 900 DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), REMARK 900 A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT REMARK 900 -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 2VV9 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE REMARK 900 RELATED ID: 2W05 RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL REMARK 900 PYRIMIDINE, COMPOUND 5B REMARK 900 RELATED ID: 2W06 RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL REMARK 900 PYRIMIDINE, COMPOUND 5C REMARK 900 RELATED ID: 2W17 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE, REMARK 900 COMPOUND (S)-8B REMARK 900 RELATED ID: 2W1H RELATED DB: PDB REMARK 900 FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA ( REMARK 900 AT9283), A MULTI-TARGETED KINASE INHIBITOR WITH POTENT REMARK 900 AURORA KINASE ACTIVITY REMARK 900 RELATED ID: 2WEV RELATED DB: PDB REMARK 900 TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF REMARK 900 CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN REMARK 900 RELATED ID: 2WFY RELATED DB: PDB REMARK 900 TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF REMARK 900 CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN REMARK 900 RELATED ID: 2WHB RELATED DB: PDB REMARK 900 TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF REMARK 900 CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN REMARK 900 RELATED ID: 2WIH RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125 REMARK 900 RELATED ID: 2WIP RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO- REMARK 900 1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-H] REMARK 900 QUINAZOLINE-3-CARBOXYLIC ACID REMARK 900 RELATED ID: 2WMA RELATED DB: PDB REMARK 900 STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION REMARK 900 OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A REMARK 900 RELATED ID: 2WMB RELATED DB: PDB REMARK 900 STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION REMARK 900 OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A REMARK 900 RELATED ID: 2WPA RELATED DB: PDB REMARK 900 OPTIMISATION OF 6,6-DIMETHYL PYRROLO 3,4-C PYRAZOLES REMARK 900 : IDENTIFICATION OF PHA-793887, A POTENT CDK INHIBITOR REMARK 900 SUITABLE FOR INTRAVENOUS DOSING REMARK 900 RELATED ID: 2WXV RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(4,3-H REMARK 900 ) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR REMARK 900 RELATED ID: 2X1N RELATED DB: PDB REMARK 900 1ST PUBLICATION TRUNCATION AND OPTIMISATION OF PEPTIDE REMARK 900 INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED REMARK 900 DESIGN 2ND PUBLICATION DESIGN, SYNTHESIS AND EVALUATION REMARK 900 OF 2-METHYL- AND 2-AMINO-N-ARYL-4,5- REMARK 900 DIHYDROTHIAZOLO (4,5-H)QUINAZOLIN-8-AMINES AS RING- REMARK 900 CONSTRAINED 2-ANILINO-4-(THIAZOL-5-YL)PYRIMIDINE CDK REMARK 900 INHIBITORS REMARK 900 RELATED ID: 2XMY RELATED DB: PDB REMARK 900 DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL- REMARK 900 5-YL)PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS REMARK 900 ANTICANCER AGENTS REMARK 900 RELATED ID: 2XNB RELATED DB: PDB REMARK 900 DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL- REMARK 900 5-YL)PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS REMARK 900 ANTICANCER AGENTS REMARK 900 RELATED ID: 4ACM RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO REMARK 900 )ETHYL]SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2- REMARK 900 CARBOXAMIDE REMARK 900 RELATED ID: 4BCF RELATED DB: PDB REMARK 900 STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2 REMARK 900 -AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 4BCG RELATED DB: PDB REMARK 900 STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2 REMARK 900 -AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 4BCH RELATED DB: PDB REMARK 900 STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2 REMARK 900 -AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 4BCI RELATED DB: PDB REMARK 900 STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2 REMARK 900 -AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 4BCJ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2 REMARK 900 -AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 4BCK RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2 REMARK 900 -AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 4BCM RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2 REMARK 900 -AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 4BCN RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2 REMARK 900 -AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 4BCO RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2 REMARK 900 -AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 4BCP RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2 REMARK 900 -AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR DBREF 4BCQ A 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 4BCQ B 171 431 UNP P30274 CCNA2_BOVIN 169 429 DBREF 4BCQ C 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 4BCQ D 171 432 UNP P30274 CCNA2_BOVIN 169 430 SEQADV 4BCQ PRO A -2 UNP P24941 EXPRESSION TAG SEQADV 4BCQ GLY A -1 UNP P24941 EXPRESSION TAG SEQADV 4BCQ SER A 0 UNP P24941 EXPRESSION TAG SEQADV 4BCQ LEU B 432 UNP P30274 EXPRESSION TAG SEQADV 4BCQ THR B 303 UNP P30274 ALA 301 CONFLICT SEQADV 4BCQ VAL B 311 UNP P30274 ILE 309 CONFLICT SEQADV 4BCQ ILE B 377 UNP P30274 VAL 375 CONFLICT SEQADV 4BCQ ARG B 378 UNP P30274 GLN 376 CONFLICT SEQADV 4BCQ SER B 387 UNP P30274 LEU 385 CONFLICT SEQADV 4BCQ MET B 391 UNP P30274 LEU 389 CONFLICT SEQADV 4BCQ LYS B 400 UNP P30274 ARG 398 CONFLICT SEQADV 4BCQ PRO C -2 UNP P24941 EXPRESSION TAG SEQADV 4BCQ GLY C -1 UNP P24941 EXPRESSION TAG SEQADV 4BCQ SER C 0 UNP P24941 EXPRESSION TAG SEQADV 4BCQ THR D 303 UNP P30274 ALA 301 CONFLICT SEQADV 4BCQ VAL D 311 UNP P30274 ILE 309 CONFLICT SEQADV 4BCQ ILE D 377 UNP P30274 VAL 375 CONFLICT SEQADV 4BCQ ARG D 378 UNP P30274 GLN 376 CONFLICT SEQADV 4BCQ SER D 386 UNP P30274 THR 384 CONFLICT SEQADV 4BCQ MET D 390 UNP P30274 CYS 388 CONFLICT SEQADV 4BCQ LYS D 400 UNP P30274 ARG 398 CONFLICT SEQRES 1 A 301 PRO GLY SER MET GLU ASN PHE GLN LYS VAL GLU LYS ILE SEQRES 2 A 301 GLY GLU GLY THR TYR GLY VAL VAL TYR LYS ALA ARG ASN SEQRES 3 A 301 LYS LEU THR GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG SEQRES 4 A 301 LEU ASP THR GLU THR GLU GLY VAL PRO SER THR ALA ILE SEQRES 5 A 301 ARG GLU ILE SER LEU LEU LYS GLU LEU ASN HIS PRO ASN SEQRES 6 A 301 ILE VAL LYS LEU LEU ASP VAL ILE HIS THR GLU ASN LYS SEQRES 7 A 301 LEU TYR LEU VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS SEQRES 8 A 301 LYS PHE MET ASP ALA SER ALA LEU THR GLY ILE PRO LEU SEQRES 9 A 301 PRO LEU ILE LYS SER TYR LEU PHE GLN LEU LEU GLN GLY SEQRES 10 A 301 LEU ALA PHE CYS HIS SER HIS ARG VAL LEU HIS ARG ASP SEQRES 11 A 301 LEU LYS PRO GLN ASN LEU LEU ILE ASN THR GLU GLY ALA SEQRES 12 A 301 ILE LYS LEU ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY SEQRES 13 A 301 VAL PRO VAL ARG THR TYR TPO HIS GLU VAL VAL THR LEU SEQRES 14 A 301 TRP TYR ARG ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR SEQRES 15 A 301 TYR SER THR ALA VAL ASP ILE TRP SER LEU GLY CYS ILE SEQRES 16 A 301 PHE ALA GLU MET VAL THR ARG ARG ALA LEU PHE PRO GLY SEQRES 17 A 301 ASP SER GLU ILE ASP GLN LEU PHE ARG ILE PHE ARG THR SEQRES 18 A 301 LEU GLY THR PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SEQRES 19 A 301 SER MET PRO ASP TYR LYS PRO SER PHE PRO LYS TRP ALA SEQRES 20 A 301 ARG GLN ASP PHE SER LYS VAL VAL PRO PRO LEU ASP GLU SEQRES 21 A 301 ASP GLY ARG SER LEU LEU SER GLN MET LEU HIS TYR ASP SEQRES 22 A 301 PRO ASN LYS ARG ILE SER ALA LYS ALA ALA LEU ALA HIS SEQRES 23 A 301 PRO PHE PHE GLN ASP VAL THR LYS PRO VAL PRO HIS LEU SEQRES 24 A 301 ARG LEU SEQRES 1 B 262 SER VAL ASN GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS SEQRES 2 B 262 THR TYR LEU ARG GLU MET GLU VAL LYS CYS LYS PRO LYS SEQRES 3 B 262 VAL GLY TYR MET LYS LYS GLN PRO ASP ILE THR ASN SER SEQRES 4 B 262 MET ARG ALA ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY SEQRES 5 B 262 GLU GLU TYR LYS LEU GLN ASN GLU THR LEU HIS LEU ALA SEQRES 6 B 262 VAL ASN TYR ILE ASP ARG PHE LEU SER SER MET SER VAL SEQRES 7 B 262 LEU ARG GLY LYS LEU GLN LEU VAL GLY THR ALA ALA MET SEQRES 8 B 262 LEU LEU ALA SER LYS PHE GLU GLU ILE TYR PRO PRO GLU SEQRES 9 B 262 VAL ALA GLU PHE VAL TYR ILE THR ASP ASP THR TYR THR SEQRES 10 B 262 LYS LYS GLN VAL LEU ARG MET GLU HIS LEU VAL LEU LYS SEQRES 11 B 262 VAL LEU THR PHE ASP LEU ALA ALA PRO THR VAL ASN GLN SEQRES 12 B 262 PHE LEU THR GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN SEQRES 13 B 262 CYS LYS VAL GLU SER LEU ALA MET PHE LEU GLY GLU LEU SEQRES 14 B 262 SER LEU ILE ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SEQRES 15 B 262 SER VAL ILE ALA ALA ALA ALA PHE HIS LEU ALA LEU TYR SEQRES 16 B 262 THR VAL THR GLY GLN SER TRP PRO GLU SER LEU ILE ARG SEQRES 17 B 262 LYS THR GLY TYR THR LEU GLU THR SER LYS PRO CYS MET SEQRES 18 B 262 LEU ASP LEU HIS GLN THR TYR LEU LYS ALA PRO GLN HIS SEQRES 19 B 262 ALA GLN GLN SER ILE ARG GLU LYS TYR LYS ASN SER LYS SEQRES 20 B 262 TYR HIS GLY VAL SER LEU LEU ASN PRO PRO GLU THR LEU SEQRES 21 B 262 ASN LEU SEQRES 1 C 301 PRO GLY SER MET GLU ASN PHE GLN LYS VAL GLU LYS ILE SEQRES 2 C 301 GLY GLU GLY THR TYR GLY VAL VAL TYR LYS ALA ARG ASN SEQRES 3 C 301 LYS LEU THR GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG SEQRES 4 C 301 LEU ASP THR GLU THR GLU GLY VAL PRO SER THR ALA ILE SEQRES 5 C 301 ARG GLU ILE SER LEU LEU LYS GLU LEU ASN HIS PRO ASN SEQRES 6 C 301 ILE VAL LYS LEU LEU ASP VAL ILE HIS THR GLU ASN LYS SEQRES 7 C 301 LEU TYR LEU VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS SEQRES 8 C 301 LYS PHE MET ASP ALA SER ALA LEU THR GLY ILE PRO LEU SEQRES 9 C 301 PRO LEU ILE LYS SER TYR LEU PHE GLN LEU LEU GLN GLY SEQRES 10 C 301 LEU ALA PHE CYS HIS SER HIS ARG VAL LEU HIS ARG ASP SEQRES 11 C 301 LEU LYS PRO GLN ASN LEU LEU ILE ASN THR GLU GLY ALA SEQRES 12 C 301 ILE LYS LEU ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY SEQRES 13 C 301 VAL PRO VAL ARG THR TYR TPO HIS GLU VAL VAL THR LEU SEQRES 14 C 301 TRP TYR ARG ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR SEQRES 15 C 301 TYR SER THR ALA VAL ASP ILE TRP SER LEU GLY CYS ILE SEQRES 16 C 301 PHE ALA GLU MET VAL THR ARG ARG ALA LEU PHE PRO GLY SEQRES 17 C 301 ASP SER GLU ILE ASP GLN LEU PHE ARG ILE PHE ARG THR SEQRES 18 C 301 LEU GLY THR PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SEQRES 19 C 301 SER MET PRO ASP TYR LYS PRO SER PHE PRO LYS TRP ALA SEQRES 20 C 301 ARG GLN ASP PHE SER LYS VAL VAL PRO PRO LEU ASP GLU SEQRES 21 C 301 ASP GLY ARG SER LEU LEU SER GLN MET LEU HIS TYR ASP SEQRES 22 C 301 PRO ASN LYS ARG ILE SER ALA LYS ALA ALA LEU ALA HIS SEQRES 23 C 301 PRO PHE PHE GLN ASP VAL THR LYS PRO VAL PRO HIS LEU SEQRES 24 C 301 ARG LEU SEQRES 1 D 262 SER VAL ASN GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS SEQRES 2 D 262 THR TYR LEU ARG GLU MET GLU VAL LYS CYS LYS PRO LYS SEQRES 3 D 262 VAL GLY TYR MET LYS LYS GLN PRO ASP ILE THR ASN SER SEQRES 4 D 262 MET ARG ALA ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY SEQRES 5 D 262 GLU GLU TYR LYS LEU GLN ASN GLU THR LEU HIS LEU ALA SEQRES 6 D 262 VAL ASN TYR ILE ASP ARG PHE LEU SER SER MET SER VAL SEQRES 7 D 262 LEU ARG GLY LYS LEU GLN LEU VAL GLY THR ALA ALA MET SEQRES 8 D 262 LEU LEU ALA SER LYS PHE GLU GLU ILE TYR PRO PRO GLU SEQRES 9 D 262 VAL ALA GLU PHE VAL TYR ILE THR ASP ASP THR TYR THR SEQRES 10 D 262 LYS LYS GLN VAL LEU ARG MET GLU HIS LEU VAL LEU LYS SEQRES 11 D 262 VAL LEU THR PHE ASP LEU ALA ALA PRO THR VAL ASN GLN SEQRES 12 D 262 PHE LEU THR GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN SEQRES 13 D 262 CYS LYS VAL GLU SER LEU ALA MET PHE LEU GLY GLU LEU SEQRES 14 D 262 SER LEU ILE ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SEQRES 15 D 262 SER VAL ILE ALA ALA ALA ALA PHE HIS LEU ALA LEU TYR SEQRES 16 D 262 THR VAL THR GLY GLN SER TRP PRO GLU SER LEU ILE ARG SEQRES 17 D 262 LYS THR GLY TYR THR LEU GLU SER LEU LYS PRO MET LEU SEQRES 18 D 262 LEU ASP LEU HIS GLN THR TYR LEU LYS ALA PRO GLN HIS SEQRES 19 D 262 ALA GLN GLN SER ILE ARG GLU LYS TYR LYS ASN SER LYS SEQRES 20 D 262 TYR HIS GLY VAL SER LEU LEU ASN PRO PRO GLU THR LEU SEQRES 21 D 262 ASN VAL MODRES 4BCQ TPO A 160 THR PHOSPHOTHREONINE MODRES 4BCQ TPO C 160 THR PHOSPHOTHREONINE HET TPO A 160 11 HET TPO C 160 11 HET TJF A1296 31 HET TJF C1295 31 HETNAM TJF 4-[4-METHYL-2-(METHYLAMINO)-1,3-THIAZOL-5-YL] HETNAM 2 TJF -2-{[3-(MORPHOLIN-4-YLCARBONYL)PHENYL]AMINO} HETNAM 3 TJF PYRIMIDINE-5-CARBONITRILE HETNAM TPO PHOSPHOTHREONINE HETSYN TPO PHOSPHONOTHREONINE FORMUL 4 TJF 2(C21 H21 N7 O2 S) FORMUL 5 TPO 2(C4 H10 N O6 P) FORMUL 6 HOH *331(H2 O) HELIX 1 1 SER A 0 GLU A 2 5 3 HELIX 2 2 PRO A 45 LYS A 56 1 12 HELIX 3 3 LEU A 87 SER A 94 1 8 HELIX 4 4 PRO A 100 HIS A 121 1 22 HELIX 5 5 LYS A 129 GLN A 131 5 3 HELIX 6 6 THR A 165 ARG A 169 5 5 HELIX 7 7 ALA A 170 LEU A 175 1 6 HELIX 8 8 THR A 182 ARG A 199 1 18 HELIX 9 9 SER A 207 GLY A 220 1 14 HELIX 10 10 GLY A 229 MET A 233 5 5 HELIX 11 11 ASP A 247 VAL A 251 5 5 HELIX 12 12 ASP A 256 LEU A 267 1 12 HELIX 13 13 SER A 276 LEU A 281 1 6 HELIX 14 14 ALA A 282 GLN A 287 5 6 HELIX 15 15 TYR B 178 CYS B 193 1 16 HELIX 16 16 TYR B 199 GLN B 203 5 5 HELIX 17 17 THR B 207 TYR B 225 1 19 HELIX 18 18 GLN B 228 LEU B 243 1 16 HELIX 19 19 LEU B 249 GLY B 251 5 3 HELIX 20 20 LYS B 252 GLU B 269 1 18 HELIX 21 21 GLU B 274 ILE B 281 1 8 HELIX 22 22 THR B 287 THR B 303 1 17 HELIX 23 23 THR B 310 PHE B 319 1 10 HELIX 24 24 LEU B 320 GLN B 322 5 3 HELIX 25 25 ASN B 326 SER B 340 1 15 HELIX 26 26 ASP B 343 LEU B 348 1 6 HELIX 27 27 LEU B 351 THR B 368 1 18 HELIX 28 28 PRO B 373 GLY B 381 1 9 HELIX 29 29 THR B 383 ALA B 401 1 19 HELIX 30 30 PRO B 402 HIS B 404 5 3 HELIX 31 31 GLN B 407 TYR B 413 1 7 HELIX 32 32 LYS B 414 HIS B 419 5 6 HELIX 33 33 GLY B 420 LEU B 424 5 5 HELIX 34 34 PRO C 45 LYS C 56 1 12 HELIX 35 35 LEU C 87 SER C 94 1 8 HELIX 36 36 PRO C 100 HIS C 121 1 22 HELIX 37 37 LYS C 129 GLN C 131 5 3 HELIX 38 38 THR C 165 ARG C 169 5 5 HELIX 39 39 ALA C 170 LEU C 175 1 6 HELIX 40 40 THR C 182 ARG C 199 1 18 HELIX 41 41 SER C 207 GLY C 220 1 14 HELIX 42 42 GLY C 229 MET C 233 5 5 HELIX 43 43 ASP C 247 VAL C 252 1 6 HELIX 44 44 ASP C 256 LEU C 267 1 12 HELIX 45 45 SER C 276 LEU C 281 1 6 HELIX 46 46 ALA C 282 GLN C 287 5 6 HELIX 47 47 TYR D 178 CYS D 193 1 16 HELIX 48 48 TYR D 199 GLN D 203 5 5 HELIX 49 49 THR D 207 TYR D 225 1 19 HELIX 50 50 GLN D 228 LEU D 243 1 16 HELIX 51 51 LEU D 249 GLY D 251 5 3 HELIX 52 52 LYS D 252 GLU D 269 1 18 HELIX 53 53 GLU D 274 ILE D 281 1 8 HELIX 54 54 THR D 287 LEU D 302 1 16 HELIX 55 55 THR D 310 PHE D 319 1 10 HELIX 56 56 LEU D 320 GLN D 322 5 3 HELIX 57 57 ASN D 326 SER D 340 1 15 HELIX 58 58 ASP D 343 LEU D 348 1 6 HELIX 59 59 LEU D 351 THR D 368 1 18 HELIX 60 60 PRO D 373 GLY D 381 1 9 HELIX 61 61 LEU D 387 LYS D 400 1 14 HELIX 62 62 ALA D 401 HIS D 404 5 4 HELIX 63 63 GLN D 407 TYR D 413 1 7 HELIX 64 64 LYS D 414 HIS D 419 5 6 HELIX 65 65 GLY D 420 LEU D 424 5 5 SHEET 1 AA 5 PHE A 4 LYS A 9 0 SHEET 2 AA 5 VAL A 18 ASN A 23 -1 O LYS A 20 N VAL A 7 SHEET 3 AA 5 VAL A 29 ARG A 36 -1 O VAL A 30 N ALA A 21 SHEET 4 AA 5 LYS A 75 GLU A 81 -1 O LEU A 76 N ILE A 35 SHEET 5 AA 5 LEU A 66 HIS A 71 -1 N LEU A 67 O VAL A 79 SHEET 1 AB 3 GLN A 85 ASP A 86 0 SHEET 2 AB 3 LEU A 133 ILE A 135 -1 O ILE A 135 N GLN A 85 SHEET 3 AB 3 ILE A 141 LEU A 143 -1 O LYS A 142 N LEU A 134 SHEET 1 AC 2 VAL A 123 LEU A 124 0 SHEET 2 AC 2 ARG A 150 ALA A 151 -1 O ARG A 150 N LEU A 124 SHEET 1 CA 5 PHE C 4 GLY C 11 0 SHEET 2 CA 5 VAL C 17 ASN C 23 -1 O VAL C 18 N ILE C 10 SHEET 3 CA 5 VAL C 29 ARG C 36 -1 O VAL C 30 N ALA C 21 SHEET 4 CA 5 LYS C 75 GLU C 81 -1 O LEU C 76 N ILE C 35 SHEET 5 CA 5 LEU C 66 HIS C 71 -1 N LEU C 67 O VAL C 79 SHEET 1 CB 3 GLN C 85 ASP C 86 0 SHEET 2 CB 3 LEU C 133 ILE C 135 -1 O ILE C 135 N GLN C 85 SHEET 3 CB 3 ILE C 141 LEU C 143 -1 O LYS C 142 N LEU C 134 SHEET 1 CC 2 VAL C 123 LEU C 124 0 SHEET 2 CC 2 ARG C 150 ALA C 151 -1 O ARG C 150 N LEU C 124 LINK N TPO A 160 C TYR A 159 1555 1555 1.33 LINK C TPO A 160 N AHIS A 161 1555 1555 1.33 LINK C TPO A 160 N BHIS A 161 1555 1555 1.33 LINK C TPO C 160 N HIS C 161 1555 1555 1.33 LINK N TPO C 160 C TYR C 159 1555 1555 1.33 CISPEP 1 VAL A 154 PRO A 155 0 -3.63 CISPEP 2 GLN B 323 PRO B 324 0 -5.75 CISPEP 3 ASP B 345 PRO B 346 0 7.15 CISPEP 4 VAL C 154 PRO C 155 0 -2.15 CISPEP 5 ASP D 345 PRO D 346 0 4.39 SITE 1 AC1 8 ILE A 10 PHE A 80 GLU A 81 LEU A 83 SITE 2 AC1 8 ASP A 86 ASN A 132 LEU A 134 ASP A 145 SITE 1 AC2 7 VAL C 18 PHE C 80 GLU C 81 LEU C 83 SITE 2 AC2 7 HIS C 84 LYS C 89 LEU C 134 CRYST1 77.080 141.160 155.520 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.012974 0.000000 0.000000 0.00000 SCALE2 0.000000 0.007084 0.000000 0.00000 SCALE3 0.000000 0.000000 0.006430 0.00000